Navigation Links
Biovista Inc. Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis
Date:9/9/2009

CHARLOTTESVILLE, Virginia, September 9 /PRNewswire/ -- Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS.

"This is our second success in MS in a period of 6 months, with BVA-201 showing efficacy levels closely comparable to those of dexamethasone," said Aris Persidis, Ph.D., President of Biovista. "Histology results are also encouraging, since they seem to confirm our expectations regarding the compound's mechanism of action. What is even more important is that BVA-201 has a known and very favorable safety profile and is already approved for chronic use," Dr. Persidis added.

For a non-confidential information pack on BVA-201 contact Biovista at info@biovista.com.

About Biovista's BVA-201 trial in the MS EAE-MOG model

MS is a chronic inflammatory neurological disease. It is the most frequent non-traumatic disabling neurologic disease among young adults, with over 2.5 million patients worldwide. In the animal proof-of-concept trial, BVA-201 was compared to dexamethasone, a potent anti-inflammatory and immunosuppressive drug that is efficient in accelerating the recovery from MS relapses but too toxic for chronic use. BVA-201 induced a statistically significant reduction of EAE severity, the magnitude of which was directly comparable to that caused by dexamethasone. Furthermore, BVA-201 protected neural axons and myelin against degeneration, as shown in the histology analysis performed. This analysis provided strong evidence that the compound works as a neuroprotective agent as opposed to most currently approved drugs that target the immune system.

About Biovista's repositioning pipeline and technology platform

Biovista applies high-throughput discovery efforts to finding solutions for commercially relevant, unmet medical needs. Biovista's proprietary repositioning technology allows the company's experts to perform mechanism-of-action based analyses and systematically assess clinical outcomes in any therapeutic area of interest, at relatively low cost and very short time spans. The company is presently using this platform to develop its own pipeline of repositioned drugs in areas such as CNS, cardiovascular disease, oncology and auto-immune diseases.

    For more information, please contact:
    Dr Aris Persidis
    Biovista, Inc.
    +1-434-242-6514
    arisp@biovista.com



'/>"/>
SOURCE Biovista Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
2. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
3. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
4. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
5. Medivation Announces Participation in Upcoming Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section
8. Verenium Announces Reverse Stock Split to Take Effect September 9
9. BPG Properties, Ltd. Announces 2750 Morris Road in Lansdale, Pennsylvania is for Sale
10. American Oriental Bioengineering Announces September Investor Conferences Participation
11. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... New York, NY (PRWEB) , ... August 15, 2017 , ... ... for the first time on Immuno-Oncology 360° (IO360°) programming through a series of upcoming ... to be held February 7-9, 2018, at The Roosevelt Hotel in New York City. ...
(Date:8/14/2017)... ... August 14, 2017 , ... ... antibodies. Key researchers in the antibody community have recently come together to address ... antibodies in the laboratory. , The team at Thermo Fisher ...
(Date:8/11/2017)... , Aug. 11, 2017  Market ... New York Times article regarding the telemedicine ... according to Kalorama Information.  The article, ... for That"  used information from Kalorama ... Monitoring & Telemedicine Market  (Sleep, Diabetes, ...
(Date:8/11/2017)... ... August 11, 2017 , ... “There is an ... natural alternatives to synthetic ingredients,” said Matt Hundt, President of Third Wave Bioactives. ... manufacturing presence and know-how of Biorigin will allow us to bring truly novel ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
Breaking Biology News(10 mins):